Innova launches nano-gold antibody tech; Imprimis snags delivery compound for eye surgery recovery;

> Innova Biosciences launched its site-specific bioconjugation technology for attaching antibodies to gold nanoparticles with more control over the orientation of the antibodies. More

> Imprimis Pharmaceuticals ($IMMY) acquired a compound for the delivery of anti-inflammatory and antibacterial agents into the eye. Release

> Arena Pharmaceuticals ($ARNA) completed a Phase I trial of its oral prostacyclin receptor agonist APD811 for the treatment of arterial hypertension. The company plans to begin Phase II in the beginning of 2014. Release

> Mallinckrodt ($MNK) said it would present clinical data next week on its extended-release oral oxycodone and acetaminophen formulation MNK-795 at PAINWeek 2013 in Las Vegas. Release

> Orexo reported successful results from a Phase II study of its sublingual formulation of alfentanil, a pain management drug for surgical and invasive diagnostic procedures. Release